<scp>TACE</scp> versus <scp>TARE</scp> for patients with hepatocellular carcinoma: Overall and individual patient level meta analysis
Andrew Brown(University of Michigan), Neehar D. Parikh(University of Michigan), Çiğdem Soydal(Ankara University), Marco Massani(AULSS 2 Marca Trevigiana), Lewis R. Roberts(Mayo Clinic), Ihab Kassab(University of Michigan), Vincent Chen(University of Michigan), Amit G. Singal(Southwestern Medical Center), Laura E. Moreno-Luna(Mayo Clinic), Whitney Townsend(University of Michigan)
Cited by 93
Related Papers
Hepatocellular carcinoma
|Nature Reviews Disease Primers|2021|6.6k
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
|Hepatology|2018|4.7k
AASLD guidelines for the treatment of hepatocellular carcinoma
|Hepatology|2017|4.2k
Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer
|Cell|2018|2.8k
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k